Safety of enzalutamide in patients with metastatic castration‐resistant prostate cancer previously treated with docetaxel: Expanded access in North America

BACKGROUND: The open‐label, single‐arm enzalutamide expanded access program (EAP) in the United States and Canada evaluated the safety of enzalutamide in patients with metastatic castration‐resistant prostate cancer (mCRPC) who had previously received docetaxel. METHODS: Patients (n = 507) received...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Prostate
Autors principals: Joshua, Anthony M., Shore, Neal D., Saad, Fred, Chi, Kim N., Olsson, Carl A., Emmenegger, Urban, Scholz, Mark, Berry, William, Mukherjee, Som D., Winquist, Eric, Haas, Naomi B., Foley, Margaret A., Dmuchowski, Carl, Perabo, Frank, Hirmand, Mohammad, Hasabou, Nahla, Rathkopf, Dana
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2015
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5024054/
https://ncbi.nlm.nih.gov/pubmed/25683285
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pros.22965
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars